title: PHARMAC responds to Stewart Mann on dihydropyridine calcium channel antagonists.
authors.forename: Andrew
authors.initials: A
authors.lastname: Davies
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Peter
authors.initials: P
authors.lastname: Moodie
authors.forename: Wayne
authors.initials: W
authors.lastname: McNee
mesh_terms: D002121:Calcium Channel Blockers / Q000191:economics* / Q000493:pharmacokinetics; D004095:Dihydropyridines / Q000191:economics* / Q000493:pharmacokinetics; D016527:Drug Costs; D004345:Drug Industry / Q000191:economics*; D016568:Drugs, Generic / Q000191:economics; D006801:Humans; D009520:New Zealand; D013810:Therapeutic Equivalency
chemical_list: D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D016568:Drugs, Generic; C038806:1,4-dihydropyridine